| Date | Title | Description | |
|---|---|---|---|
| 07 Nov 2024 | On P&L | The Company releases the press release related to the first nine months 2024 financial results | Download |
| 07 Nov 2024 | On P&L | The Company releases the first nine months 2024 financial results presentation | Download |
| 24 Oct 2024 | On corporate transactions | ROVI completes the strategic review of its CDMO business | Download |
| 31 Jul 2024 | On P&L | The Company releases the press release related to the first half 2024 financial results | Download |
| 31 Jul 2024 | On P&L | The Company releases the first half 2024 financial results presentation | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 26 Feb 2020 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2019 annual report regarding remuneration of the members of the Board of Directors | Download |
| 26 Feb 2020 | Information on P&L | ROVI releases the press release related to the full year 2019 financial results | Download |
| 26 Feb 2020 | Information on P&L | ROVI releases the full year 2019 results presentation | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 05 Oct 2017 | Contratos de liquidez y contrapartida | Liquidity contract: modification of transactions conducted from 11 July to 30 September 2017. | Download |
| 03 Oct 2017 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted from 11 July to 30 September 2017 | Download |
| 07 Sep 2017 | Otros sobre negocio y situación financiera | The Company informs that commences the enoxaparin biosimilar marketing in Germany | Download |
| 26 Jul 2017 | Información sobre resultados | ROVI releases the presentation related to the 2017 first half results | Download |
| 26 Jul 2017 | Información sobre resultados | ROVI releases the presentation related to the 2017 first half results | Download |